SCHEMBL29980096

SCHEMBL29980096

Fc1cc(F)cc(CSc2ccc3ccccc3n2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 4/20 0.49
▸ PRNP P04156 4/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ L3MBTL1 Q9Y468 4/20 0.48
▸ NPSR1 Q6W5P4 3/20 0.47
▸ MAPK10 P53779 2/20 0.47
▸ RAB9A P51151 3/20 0.46
▸ KMT2A Q03164 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 4/20 0.40
▸ LMNA P02545 2/20 0.40
▸ PTBP1 P26599 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ NPC1 O15118 2/20 0.38
▸ HTT P42858 1/20 0.38
▸ AR P10275 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20338474 1.00 RXFP1 (0.49) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1
SCHEMBL29177611 0.82 RXFP1 (0.60) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1
Ammonia Solution, Strong SCHEMBL28220202 0.79 RXFP1 (0.57) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1
SCHEMBL1061506 0.76 RXFP1 (0.50) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1
SCHEMBL29980697 0.76 MAOB (0.51) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1
SCHEMBL19810854 0.76 MAOB (0.51) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1
SCHEMBL11189080 0.72 RXFP1 (0.60) RXFP1PRNPKDM4ESMN1; SMN2NPSR1
SCHEMBL12795599 0.71 PRNP (0.61) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1
SCHEMBL11029724 0.71 PRNP (0.59) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1
SCHEMBL8347789 0.71 PRNP (0.59) RXFP1PRNPKDM4ESMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11464770-B2 Anticancer pharmaceutical composition KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2022-10-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11464770-B2 Anticancer pharmaceutical composition MYC, MYCBP, TP53 RXFP1 4869/4885PRNP 1647/4885KDM4E 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback